GLENMARK - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.4
| Stock Code | GLENMARK | Market Cap | 59,188 Cr. | Current Price | 2,098 ₹ | High / Low | 2,298 ₹ |
| Stock P/E | 39.9 | Book Value | 848 ₹ | Dividend Yield | 0.12 % | ROCE | 9.72 % |
| ROE | 7.35 % | Face Value | 1.00 ₹ | DMA 50 | 2,069 ₹ | DMA 200 | 1,919 ₹ |
| Chg in FII Hold | -1.53 % | Chg in DII Hold | 1.48 % | PAT Qtr | 426 Cr. | PAT Prev Qtr | 193 Cr. |
| RSI | 48.7 | MACD | 37.9 | Volume | 4,86,828 | Avg Vol 1Wk | 6,54,022 |
| Low price | 1,336 ₹ | High price | 2,298 ₹ | PEG Ratio | 20.0 | Debt to equity | 0.02 |
| 52w Index | 79.2 % | Qtr Profit Var | 3.00 % | EPS | 0.74 ₹ | Industry PE | 27.2 |
📊 Analysis: Glenmark Pharmaceuticals shows weak efficiency metrics with ROCE at 9.72% and ROE at 7.35%, which are below industry standards. The company is nearly debt-free (0.02 debt-to-equity), which adds financial stability. Valuation-wise, the P/E of 39.9 is higher than the industry average of 27.2, suggesting overvaluation. The PEG ratio of 20.0 further highlights poor growth prospects relative to price. Dividend yield of 0.12% is negligible. Technical indicators (RSI 48.7, MACD 37.9) show neutral-to-positive momentum, with the stock trading slightly above DMA 50 and DMA 200, indicating short-term strength despite weak fundamentals.
💰 Entry Price Zone: Considering valuations and recent momentum, the ideal entry zone is ₹1,850–₹1,950, closer to support levels and below DMA 200 (₹1,919). This range offers better risk-reward compared to current levels.
📈 Exit / Holding Strategy: For long-term investors, Glenmark’s weak ROE/ROCE and high PEG ratio suggest limited compounding potential. Holding period should be short-to-medium term (1–2 years). Exit strategy should involve profit booking near ₹2,250–₹2,300 if valuations stretch further. Long-term holding is not recommended unless efficiency metrics improve significantly.
✅ Positive
- Debt-free balance sheet ensures financial safety.
- Strong quarterly PAT growth from ₹193 Cr. to ₹426 Cr.
- DII holdings increased (+1.48%), showing domestic confidence.
- Stock trading above DMA 200 indicates short-term strength.
⚠️ Limitation
- ROE (7.35%) and ROCE (9.72%) are weak compared to peers.
- PEG ratio of 20.0 suggests poor growth prospects.
- Dividend yield of 0.12% is negligible.
📉 Company Negative News
- Decline in FII holdings (-1.53%).
- High P/E compared to industry average, indicating overvaluation.
📈 Company Positive News
- Quarterly PAT more than doubled sequentially.
- DII confidence increased significantly (+1.48%).
- EPS growth visible, though still modest at ₹0.74.
🏭 Industry
- Pharmaceutical sector benefits from global demand and healthcare expansion.
- Industry PE of 27.2 reflects moderate optimism in the sector.
📝 Conclusion
Glenmark Pharmaceuticals shows short-term momentum but weak long-term fundamentals due to low ROE/ROCE and high PEG ratio. Ideal entry is around ₹1,850–₹1,950. Investors should treat this as a short-to-medium term opportunity, with profit booking near ₹2,250–₹2,300. Long-term holding is not advisable unless efficiency metrics improve.